Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cullinan MICA
Cambridge, Massachusetts, United Statescullinanoncology.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Cullinan MICA’s lead candidate, CLN-619, is a humanized IgG1 monoclonal antibody targeting MICA/MICB. It is being tested in Phase 1 trials for relapsed/refractory multiple myeloma and advanced solid tumors, aiming to overcome immune evasion by restoring tumor cell recognition and promoting NK/T cell-mediated lysis. Early studies show a clean safety profile in non-human primates
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibody
- Industry
- Biotech
02
Partnerships
Avalon VenturesBregua CorporationMyeloma Investment Fund (Multiple Myeloma Research Foundation)PDI Therapeutics
Beyond the preview
Go deeper on Cullinan MICA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cullinan MICA.